Alnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $146.07 +0.19%
EPS Growth %: -7.5%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
SFST, VLTO, CLIR, More
EPS Growth %: -7.5%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
- Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance
- Baker Hughes Company (BKR) Tops Q1 EPS by 4c, Beats on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
